Drug Trial Radar · NCT06689163
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
Last checked: Nov 20, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Dec 11, 2024
Primary completion
Nov 30, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.
Conditions
- Prostate Cancer
Interventions
HRS-1167 tabletsDrug
HRS-1167 tablets
Abiraterone Acetate tablets(II)Drug
Abiraterone Acetate tablets(II)
Prednisone Acetate tabletsDrug
Prednisone Acetate tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: 28 days
- Recommended phase II dose (RP2D)Time frame: 28 days
- The dose suspension rate caused by drug-related adverse eventsTime frame: 2 years
- The dose downregulation rate caused by drug-related adverse eventsTime frame: 2 years
- The dose termination rate caused by drug-related adverse eventsTime frame: 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital Of Anhui Medical University
Hefei, Anhui, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.